

Adrenocorticotrophic Hormone Receptor - Pipeline Review, H2 2020

<https://marketpublishers.com/r/A69A606C7BC7EN.html>

Date: October 2020

Pages: 62

Price: US\$ 3,500.00 (Single User License)

ID: A69A606C7BC7EN

Abstracts

Adrenocorticotrophic Hormone Receptor - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Adrenocorticotrophic Hormone Receptor - Pipeline Review, H2 2020'; Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 6 molecules.

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotrophic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.

The report 'Adrenocorticotrophic Hormone Receptor - Pipeline Review, H2 2020' outlays comprehensive information on the Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Hormonal Disorders, Immunology, Metabolic Disorders, Musculoskeletal

Disorders and Undisclosed which include indications Infantile Spasm (West Syndrome), Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Multiple Sclerosis, Pituitary ACTH Hypersecretion (Cushing Disease), Rheumatoid Arthritis and Unspecified.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropin Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)

The report reviews Adrenocorticotropin Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Adrenocorticotropin Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Adrenocorticotropin Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Adrenocorticotropin Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or

ACTHR or MC2R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Overview

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development

Aequus BioPharma Inc

Crinetics Pharmaceuticals Inc

Eton Pharmaceuticals Inc

Ferring Pharmaceuticals Inc

Mallinckrodt Plc

Upsher-Smith Laboratories LLC

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles

AMZ-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cosyntropin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Adrenal Corticotrophic Hormone Receptor for Cushing

Disease and Congenital Adrenal Hyperplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Products

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products

Adrenocorticotrophic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Product Development Milestones

Featured News & Press Releases

Oct 20, 2020: City of Rockford \$10 billion lawsuit against pharmaceutical giant
Mallinckrodt threatened by bankruptcy

Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision
denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with
the Centers for Medicare and Medicaid Services (CMS)

Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision
denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with
the Centers for Medicare and Medicaid Services (CMS)

Jun 01, 2020: Mallinckrodt will appeal District Court ruling in case involving ongoing
Acthar medicaid drug rebate dispute with the Centers for Medicare and Medicaid
Services (CMS)

Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository
Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4

study in rheumatoid arthritis (RA) in Rheumatology and Therapy

Mar 16, 2020: Mallinckrodt confirms court decision in lawsuit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and provides update related to global opioid settlement and present financing activities

Mar 05, 2020: Data on Acthar Gel (repository corticotropin injection) therapy in immunoglobulin a nephropathy (IgAN) published in Kidney International Reports

Mar 04, 2020: Mallinckrodt announces publication of new data on Acthar Gel (Repository Corticotropin Injection) in rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis published in Open Access Rheumatology: Research and Reviews

Feb 27, 2020: Mallinckrodt to present new data from two studies on Acthar Gel (Repository Corticotropin Injection) therapy in Multiple Sclerosis (MS) relapse at Fifth Annual ACTRIMS Forum 2020

Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis

Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease

Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting

Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population

Oct 01, 2019: Mallinckrodt announces positive top-line findings from its observational registry assessing relapse recovery in multiple sclerosis relapse patients treated with Acthar Gel (Repository Corticotropin Injection)

Sep 13, 2019: Mallinckrodt analysis suggests Acthar Gel may be a cost-effective option compared to other late-line, adult treatments for Multiple Sclerosis Relapse

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Aequus BioPharma Inc, H2 2020

Pipeline by Crinetics Pharmaceuticals Inc, H2 2020

Pipeline by Eton Pharmaceuticals Inc, H2 2020

Pipeline by Ferring Pharmaceuticals Inc, H2 2020

Pipeline by Mallinckrodt Plc, H2 2020

Pipeline by Upsher-Smith Laboratories LLC, H2 2020

Dormant Projects, H2 2020

Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Adrenocorticotrophic Hormone Receptor - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/A69A606C7BC7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A69A606C7BC7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970